Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azvudine + dosimertinib
- Development stage
- Preclinical
- Lead developer
- Genuine Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Azvudine + dosimertinib is a small molecule combination therapy being developed by Bio Genuine (Genuine Biotech) for the treatment of non-small cell lung cancer (NSCLC). Dosimertinib is a clinical-stage, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed to target EGFR mutations, including the T790M resistance mutation; preclinical data suggests it achieves higher concentrations in lung and brain tissues compared to osimertinib. Azvudine, originally developed as a nucleoside reverse transcriptase inhibitor for viral infections, acts in this oncology context as an immunomodulator that significantly reduces the levels of myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment. By combining these two agents, the therapy aims to provide synergistic anti-tumor effects by simultaneously blocking oncogenic EGFR signaling and alleviating MDSC-mediated immunosuppression. Bio Genuine submitted an Investigational New Drug (IND) application for this combination to China's NMPA in November 2024.
- Other names
- Azvudine/Dosimertinib
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)Vif (HIV-1 Vif)RdRp (Coronavirus RNA-dependent RNA polymerase)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on azvudine + dosimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azvudine + dosimertinib.